On Tuesday, Shares of SunTrust Banks, Inc. (NYSE:STI), gained 1.34% to $44.00.
SunTrust Banks, Inc. (STI) declared that it plans to release fourth quarter 2015 results on Friday, January 22, 2016. SunTrust administration will host a conference call that morning.
SunTrust Banks, Inc. operates as the holding company for SunTrust Bank that provides various financial services in the United States. The company operates in three segments: Consumer Banking and Private Wealth Administration, Wholesale Banking, and Mortgage Banking.
Shares of Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF), inclined 1.43% to $3.55, during its last trading session.
Can-Fite Bio Pharma Ltd., stated financial results for the nine months ended September 30, 2015 and updates on its drug development programs.
Clinical Development Program and Corporate Highlights Comprise:
- Fortifies Balance Sheet with $13.8 Million Fund Raise
During September 2015, Can-Fite closed on about $9 million in funding from institutional investors. As of September 30, 2015 Can-Fite had cash and cash equivalents of $14.46 million. In October the Company raised an additional $4.8 million.
- CF102 – Receives Fast Track Designation in U.S. & Orphan Drug Designation in Europe; Reports Compelling Preclinical Data and Files Patent for NASH
During, and right away following, the third quarter of 2015, three noteworthy events moved CF102’s clinical development forward. 1) The U.S. Food and Drug Administration (FDA) granted Fast Track Designation to CF102 as a second line treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer. With Fast Track CF102 benefits from more frequent meetings and communications with the FDA to review the drug’s development plan to support approval, while also allowing the Company to submit parts of the New Drug Application (NDA) on a rolling basis for review as data becomes available. CF102 also has the FDA’s Orphan Drug Designation. 2) In October 2015, the European Medicines Agency (EMA) granted Orphan Drug Designation to CF102 for the indication of HCC, giving CF102 protocol assistances and a 10-year market exclusivity following market approval in 28 EU member states and 3 additional European Economic Area countries. Can-Fite continues to enroll and dose patients in its global Phase II liver cancer study. About 78 patients are predictable to be enrolled in the trial in the U.S., Europe, and Israel by June 30, 2016. 3) In November 2015, the Company stated data from a preclinical study of an animal model of non-alcoholic steatohepatitis (NASH), revealing CF102 had a statistically noteworthy reduction in liver pathology. This data supports the development of CF102 for NASH, which represents a large and unmet medical need, with no U.S. FDA approved treatment presently available. The addressable market for the treatment of NASH in 2025 is estimated at $35-$40 billion by Deutsche Bank. Can-Fite filed a patent for CF102 in the treatment of NASH.
Can-Fite Bio Pharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. It offers CF101, which has accomplished Phase II/III clinical trials for the treatment of psoriasis; accomplished Phase II clinical trials for the treatment of rheumatoid arthritis; accomplished Phase I clinical study for the treatment of osteoarthritis; and accomplished Phase I study for the treatment of uveitis, in addition to is in Phase II clinical trials for the treatment of glaucoma or related syndromes of ocular hypertension.
Finally, Shares of Analog Devices, Inc. (NASDAQ:ADI), ended its last trade with -0.10% loss, and closed at $61.57.
Analog Devices, declared that the company has been named one of the world’s most innovative corporations according to the Thomson Reuters 2015 Top 100 Global Innovator program. Using proprietary data and analysis tools, the Thomson Reuters award program identifies companies and organizations that are world leaders in innovation. This is the fourth time in five years that Analog Devices has been so recognized.
“Impactful innovation has been the hallmark of Analog Devices’ success for the past 50 years and guides every step of our customer engagement,” said Peter Real, senior vice president and chief technology officer, Analog Devices. “We are honored to be selected yet again by Thomson Reuters for solving our customers’ toughest problems, enabling important new discoveries and intelligently bridging the physical and digital worlds with technologies that sense, measure and connect.”
The Thomson Reuters 2015 Top 100 Global Innovator methodology is based on four principle criteria: overall patent volume, patent application-to-grant success rate, global reach of the portfolio, and patent influence as evidenced by citations. This objective formula identifies the companies around the world that are discovering new inventions, commercializing them and protecting them from infringers.
Analog Devices, Inc. designs, manufactures, and markets a portfolio of solutions that leverage analog, mixed-signal, and digital signal processing technology, counting integrated circuits (ICs), algorithms, software, and subsystems.